Evidence map›Paper›PMID 12391289›Full record

ArticleMolecular pharmacology2002

Quantitation of the P2Y(1) receptor with a high affinity radiolabeled antagonist.

Gary L Waldo, James Corbitt, José L Boyer, Gnana Ravi, Hak Sung Kim, Xiao-Duo Ji, James Lacy, Kenneth A Jacobson, T Kendall Harden

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmacology, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
5.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 90 citations in OpenAlex.

  1. Advances in nucleotide-based P2Y₁ antagonism: implications for cardiovascular therapeutics.Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents · 2026
    Review
  2. Review
  3. Design and Pharmacological Characterization of a Novel Antithrombotic P2YInternational journal of molecular sciences · 2025
    Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. P2 receptors and platelet function.Purinergic signalling · 2011
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Gary L WaldoDepartment of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599, USA.
James Corbitt
José L Boyer
Gnana Ravi
Hak Sung Kim
Xiao-Duo Ji
James Lacy
Kenneth A Jacobson
T Kendall Harden
National Institute of Diabetes and Digestive and Kidney Diseases · USNational Institutes of Health · USPerkinElmer (United States) · USUniversity of North Carolina at Chapel Hill · US

Funding

P2Y-PURINERGIC RECEPTORSR01GM038213 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HARDEN, T KENDALL · 1987 to 2012
$3.9M
P2T PURINERGIC RECEPTORSR01HL054889 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI BOYER, JOSE L · 2001 to 2004
$1.0M
PROSTHETIC GROUPS FOR RADIOLABELING OF FUNCTIONALIZED DRUGS AND PEPTIDESZ01DK031116 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI JACOBSON, KENNETH ALAN · 1991 to 2008
$769k
P2T-PURINERGIC RECEPTORSR29HL054889 · NHLBI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI BOYER, JOSE L · 1995 to 1999
–
Intramural NIH HHS Z01 DK031116Intramural NIH HHS Z99 DK999999NHLBI NIH HHS HL54889NHLBI NIH HHS R01 HL054889NHLBI NIH HHS R29 HL054889NIGMS NIH HHS GM38213NIGMS NIH HHS R01 GM038213
6 · The paper itself

Abstract

2-Chloro-N(6)-methyl-(N )-methanocarba-2'-deoxyadenosine-3',5'- bisphosphate (MRS2279) was developed previously as a selective high-affinity, non-nucleotide P2Y(1) receptor (P2Y1-R) antagonist (J Med Chem 43:829-842, 2002; Br J Pharmacol 135:2004-2010, 2002). We have taken advantage of the N(6)-methyl substitution in the adenine base to incorporate [(3)H]methylamine into the synthesis of [(3)H]MRS2279 to high (89 Ci/mmol) specific radioactivity and have used this molecule as a radioligand for the P2Y1-R. [(3)H]MRS2279 bound to membranes from Sf9 insect cells expressing recombinant human P2Y1-R but not to membranes from wild-type Sf9 cells or Sf9 cells expressing high levels of recombinant P2Y(2) or P2Y(12) receptors. Equilibrium binding of [(3)H]MRS2279 to P2Y1-R expressed in Sf9 membranes was with a high affinity (K(d) = 8 nM) essentially identical to the apparent affinity of MRS2279 determined previously in studies of P2Y1-R-promoted inositol phosphate accumulation or platelet aggregation. A kinetically derived K(d) calculated from independent determinations of the rate constants of association (7.15 x 10(7) M(-1) min(-1)) and dissociation (0.72 min(-1)) of [(3)H]MRS2279 also was in good agreement with the K(d) derived from equilibrium binding studies. Competition binding assays with [(3)H]MRS2279 and P2Y1-R expressing Sf9 cell membranes revealed K(i) values for the P2Y1-R antagonists MRS2279 (K(i) = 13 nM), N(6)-methyl-2'-deoxyadenosine-3',5'-bisphosphate (MRS2179; K(i) = 84 nM), adenosine-3', 5'-bisphosphate (K(i)=900 nM), and pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid (K(i) = 6 microM) that were in good agreement with antagonist activities of these molecules previously determined at the P2Y1-R in intact tissues. Moreover, [(3)H]MRS2279 also bound with high affinity (K(d) = 4-8 nM) to Chinese hamster ovary (CHO) or 1321N1 human astrocytoma cells stably expressing the human P2Y1-R, but specific binding was not observed in wild-type CHO or 1321N1 cells. [(3)H]MRS2279 bound with high affinity (K(d) = 16 nM) to a binding site on out-dated human platelets (5-35 receptors/platelet) and rat brain membranes (210 fmol/mg protein) that fit the expected drug selectivity of a P2Y1-R. Taken together, these results indicate that [(3)H]MRS2279 is the first broadly applicable antagonist radioligand for a P2Y receptor.

Indexed as

Adenosine DiphosphateAnimalsCells, CulturedFemaleHumansInsectaPurinergic P2 Receptor AntagonistsRadiopharmaceuticalsRatsRats, Sprague-DawleyReceptors, Purinergic P2Receptors, Purinergic P2Y1Tritium2-chloro-N6-methyl-(N)-methanocarba-2'-deoxyadenosine-3',5'-bisphosphateAdenosine DiphosphateP2RY1 protein, humanP2ry1 protein, ratPurinergic P2 Receptor AntagonistsRadiopharmaceuticalsReceptors, Purinergic P2Receptors, Purinergic P2Y1Tritium

Identifiers

PMID12391289
PMCPMC4367814
OpenAlexW2135828647

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.